Tag: AbbVie
Medincell joins forces with AbbVie to develop up to 6 products – 04/17/2024 at 10:15 a.m.
(AOF) – Medincell announced an agreement with the American AbbVie to co-develop and market up to six products in different therapeutic areas and indications. The biotech specialist in long-acting injectable…
Medincell: the stock rises after the agreement concluded with AbbVie – 04/17/2024 at 10:59
(CercleFinance.com) – Medincell shares jumped Wednesday morning on the Paris Stock Exchange after the signing of a strategic agreement with the American AbbVie, known for its flagship drug against rheumatoid…
OSE: entry into force of the license agreement with AbbVie – 04/17/2024 at 2:11 p.m.
(CercleFinance.com) – OSE Immunotherapeutics announced on Wednesday the entry into force of its global licensing agreement with AbbVie, aimed at developing a monoclonal antibody for the treatment of chronic inflammation.…
Medincell will present the strategic co-development and licensing agreement with AbbVie during a webinar on April 17 at 10:00 a.m. CEST – 04/16/2024 at 6:30 p.m.
Strategy, framework of the collaboration, financial terms of the agreement, prospects for Medincell: management invites you to a webinar presenting the co-development and licensing agreement with AbbVie Register by clicking…
OSE Immunotherapeutics: partnership with AbbVie for OSE-230
By Arnaud Bivès Published on 02/28/2024 at 7:57 a.m. (Boursier.com) — OSE Immunotherapeutics and AbbVie announce a…
OSE Immuno: the title soars, partnership with AbbVie – 02/28/2024 at 11:45
(CercleFinance.com) – OSE Immunotherapeutics shares soared on the Paris Stock Exchange on Wednesday following the signing of a strategic partnership with the American biopharmaceutical group AbbVie. Around 11:30 a.m., the…
Ose Immunotherapeutics jumps after its partnership with Abbvie
(AOF) – Ose Immunotherapeutics (+54.61% to 5.11 euros) posts the strongest increase in the SRD market after announcing a global collaboration and licensing agreement with the American Abbvie to develop…
AbbVie: 22% drop in EPS in the 4th quarter
(CercleFinance.com) – AbbVie publishes adjusted EPS of $2.79 for the fourth quarter of 2023, down 22.5%, with an adjusted operating margin of 43.8% for revenue of $14.3 billion, down 5.4%.…
AbbVie: Botox warning?
By Jean-Noel Legalland Posted on 10/28/2022 at 1:58 p.m. Photo credit © UzirePictures …
Inventiva: AbbVie stops developing a cedirogant for autoimmune diseases – 10/31/2022 at 08:48
(AOF) – Inventiva, a biopharmaceutical company, announced that AbbVie has announced the discontinuation of development of cedirogant (ABBV-157), an oral RORy inverse agonist jointly discovered by Inventiva and AbbVie for…
Inventiva: The development of AbbVie treatment in autoimmune diseases is abandoned
(BFM Bourse) – The stock market price of the Burgundian biotechnology firm fell after AbbVie announced it was stopping development of cedirogant for the treatment of autoimmune diseases. Inventiva still…
AbbVie: 5% dividend increase
(CercleFinance.com) – On the occasion of the publication of its quarterly reports, AbbVie announces a 5% increase in its dividend for 2023, thus fixing the quarterly installment at 1.48 dollars…